Jpmorgan Chase & CO Sage Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 150,823 shares of SAGE stock, worth $769,197. This represents 0.0% of its overall portfolio holdings.

Number of Shares

150,823

Previous 1,199,975 87.43%

Holding current value

$769,197

Previous $13 Million 91.66%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$7.02 - $13.08 $7.37 Million - $13.7 Million	-1,049,152 Reduced 87.43%	150,823 $1.09 Million
Q2 2024 Aug 12, 2024	BUY	$10.58 - $17.9 $478,840 - $810,136	45,259 Added 3.92%	1,199,975 $13 Million
Q1 2024 May 10, 2024	SELL	$18.62 - $26.95 $9.61 Million - $13.9 Million	-515,999 Reduced 30.88%	1,154,716 $21.6 Million
Q4 2023 Feb 12, 2024	BUY	$17.1 - $22.26 $37,568 - $48,905	2,197 Added 0.13%	1,670,715 $36.2 Million
Q3 2023 Nov 14, 2023	SELL	$16.75 - $48.98 $403,273 - $1.18 Million	-24,076 Reduced 1.42%	1,668,518 $34.3 Million
Q2 2023 Aug 11, 2023	BUY	$40.65 - $59.54 $12.9 Million - $18.9 Million	317,276 Added 23.07%	1,692,594 $79.6 Million
Q1 2023 May 18, 2023	BUY	$37.27 - $46.57 $2.43 Million - $3.04 Million	65,256 Added 4.98%	1,375,318 $57.7 Million
Q1 2023 May 11, 2023	SELL	$37.27 - $46.57 $3.83 Million - $4.79 Million	-102,769 Reduced 7.27%	1,310,062 $55 Million
Q4 2022 Feb 13, 2023	SELL	$32.2 - $43.61 $3.73 Million - $5.06 Million	-115,916 Reduced 7.58%	1,412,831 $53.9 Million
Q3 2022 Nov 14, 2022	SELL	$32.28 - $43.27 $733,401 - $983,094	-22,720 Reduced 1.46%	1,528,747 $59.9 Million
Q2 2022 Aug 11, 2022	SELL	$27.52 - $37.99 $1.71 Million - $2.36 Million	-62,183 Reduced 3.85%	1,551,467 $50.1 Million
Q1 2022 May 11, 2022	BUY	$30.71 - $45.71 $1.6 Million - $2.38 Million	52,028 Added 3.33%	1,613,650 $53.4 Million
Q4 2021 Feb 10, 2022	BUY	$37.06 - $47.11 $14.7 Million - $18.7 Million	397,001 Added 34.09%	1,561,622 $66.4 Million
Q3 2021 Nov 12, 2021	BUY	$40.26 - $57.37 $46.9 Million - $66.8 Million	1,164,621 New	1,164,621 $51.6 Million

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $303M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Sage Therapeutics, Inc. Transaction History